AIRS · Airsculpt Technologies, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 10, 2026TL;DR. AirSculpt reported Q2 revenue down 3% to $42.9M with adjusted EBITDA of $4.9M (vs. $5.8M), cut its full-year adjusted EBITDA outlook to $12–$14M, and reaffirmed revenue at the low end of $151–$157M; same-center cases grew 1% and the company expanded its AlloClae partnership and new procedures, while customer acquisition cost rose to ~$3,500 from $2,900.
- + Same-center case volume grew 1.0% in Q2 and 1.1% YTD versus prior year.
- + Entered an exclusive AlloClae partnership and is piloting the new procedure later this quarter.
- + Skin tightening and skin removal procedures carry similar ~60% gross margin profile to core fat removal business and lift average ticket.
- − Q2 revenue declined 3% to $42.9M and YTD revenue fell 1.3% to $82.3M.
- − Adjusted EBITDA fell to $4.9M in Q2 from $5.8M and YTD to $8.2M from $9.6M, with margins compressing to 11.5%/10.0% from 13.3%/11.5%.
- − Full-year 2026 adjusted EBITDA outlook reduced to approximately $12–$14M.
- − Full-year 2026 revenue reaffirmed only at the lower end of the $151–$157M guidance range.
- − Q2 customer acquisition cost rose to ~$3,500 from ~$2,900 a year ago, lifting marketing to ~20% of revenue from ~18%.
- − Q2 net loss widened to $1.1M from $0.6M and YTD net loss to $3.5M from $3.4M.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AIRS
this stock
Airsculpt Technologies, Inc.
|
$189.61M | +41.2% | -15.8% | — | 3.9% |
|
HCA
HCA Healthcare, Inc.
|
$91.28B | -13.3% | +7.1% | 14.2 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.22B | -11.2% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.22B | +33.4% | +0.9% | 10.2 | 3.1% |
|
FMS
Fresenius Medical Care AG
|
$12.05B | -4.9% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AIRS | +7.5% | -44.2% | -0.4% | +10.9% | +41.2% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +7.4% | -43.8% | -15.5% | +10.5% | +28.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.